Protein Assays Market Size, Share & Industry Analysis, By Product Type (Kits, Reagents & Consumables, and Instruments), By Technology (Colorimetric Protein Quantification, Fluorometric Protein Quantification, Luminescent Protein Quantification, ELISA-Based Protein Quantification, and Others), By Application (Drug Discovery & Development, Proteomics & Molecular Biology, Clinical Diagnostics & Disease Research, and Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical & Diagnostic Laboratories, and Others), and Regional Forecast, 2026-2034

The global protein assays market size was valued at USD 2.74 billion in 2025. The market is projected to grow from USD 2.94 billion in 2026 to USD 5.15 billion by 2034, exhibiting a CAGR of 7.29% during the forecast period.

The market is witnessing a noteworthy growth trajectory during the forecast period. Protein assays are used to measure the concentration of protein in a solution. It is mainly used for drug discovery, proteomics, clinical diagnostics, and biological research, which is used to find the enzyme activity, biomarker analysis, and protein development for therapeutic purposes, and others.

Furthermore, rising demand for biotechnology product research and development, and a rising number of investments and fundraising activities are expected to boost the global market growth.

• For instance, in July 2024, Spear Bio Inc. received USD 45.0 million in Series A funding. This funding was used to accelerate product launch for protein research and disease diagnostics.

Moreover, the market encompasses several major players with Thermo Fisher Scientific Inc., Agilent, and Danaher at the forefront. The robust portfolio and strategic activities support the dominance of these companies in the market.

MARKET DYNAMICS

MARKET DRIVERS:

Increasing Development of Protein Therapeutics to Propel Market Growth

The increasing focus of the pharmaceutical industry and biotechnology companies to create novel protein-based drugs to treat various diseases is one of the most prominent driving factors of the market. This increases the demand for protein assays to support research, development, and quality control processes.

• For instance, in November 2025, Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had approval REDEMPLO (plozasiran), for the development of a small interfering RNA (siRNA) medicine protein assay was used, for the development of which was used to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

MARKET RESTRAINTS:

Product Recalls of Protein Assay Instruments to Restrict Market Growth

The product recall of the instruments and devices used for protein assays hampers the brand image and consumers' trust, thus restricting the market growth.

• For instance, in August 2023, the FDA reported the class 2 device recall for Siemens Atellica CH Total Protein II (TP) assay due to reagent carryover from LDL Cholesterol Direct, Total Protein II, Triglycerides, and Triglycerides 2 impacting magnesium (Mg) Such factors restrict product adoption and market growth.

MARKET OPPORTUNITIES:

Development of MS-Compatible Assays to Create Lucrative Growth Opportunities

Currently available assays often face limitations such as low sensitivity, limited dynamic range, and interference from complex biological samples. Also, existing methods may require extensive sample preparation that increases the time and costs. To address such issues, key market players are focused on developing and launching innovative, robust assay platforms for detection accuracy and simplifying workflows.

• In August 2025, Precision Quantomics launched MSQ-DILI, a next-generation Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) based assay kit. Also, they expanded their Quantitative Proteomics Services to support the qualification of emerging human drug testing platforms, including organoids and micro-physiological systems (MPS).

PROTEIN ASSAYS MARKET TRENDS:

Integration with Automation & AI-Based Platforms to Support Market Growth

The rising focus on AI integration and automation of platforms to automate workstations and routine laboratory experiments to reduce hands-on time and ensure consistency in results across diverse experimental settings.

• For instance, in July 2025, Merck KGaA launched the AAW Automated Assay Workstation, powered by Opentrons, which helps in lab automation for automation of laboratory experiments. It is extensively used for libraries across protein, molecular, and cell biology applications.

Download Free sample to learn more about this report.

MARKET CHALLENGES:

Limited Availability of Skilled Personnel to Challenge Market Growth

A shortage of trained professionals may challenge the protein assays market growth as protein assays are complex laboratory procedures that require specialized knowledge and technical expertise.

Limited availability of skilled professionals may hinder the implementation and scalability of protein assay techniques across research institutions and clinical laboratories.

Segmentation Analysis

By Product Type

Increasing Product Launches of Kits to Propel Segmental Growth

The product type segment is divided into kits, reagents & consumables, and instruments.

The kits segment held a dominant portion of the protein assays market share in 2024. The growth of the segment is driven by increasing adoption of kits for protein assay, biomarker tests. Also, rising product launches associated with kits are expected to boost the segment’s growth in the market.

• For instance, in November 2025, Abselion announced the expansion of its Amperia assay portfolio with the launch of the Tagged Protein Quantification Kit, His-tag, and Tagged Protein Sensor, His-tag Quantification. These products are used for recombinant protein analysis and help researchers generate high-quality data.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Increasing Adoption and Convenience Bolster Colorimetric Protein Quantification Segment’s Growth

In terms of technology, the market is categorized into colorimetric protein quantification, fluorometric protein quantification, luminescent protein quantification, ELISA-based protein quantification, and others.

The colorimetric protein quantification segment held the maximum portion of the market. In 2025, the segment is anticipated to dominate with a 35.9% share. The maximum share of the segment is due to its compatibility with routine laboratory workflows, as it is inexpensive and easy to use.

The fluorometric protein quantification segment is expected to grow at a CAGR of 11.30% over the forecast period. The maximum growth during the forecast period is due to increasing adoption of fluorometric assays for accurate and efficient results during protein analysis, and rising product launches by key players are also contributing toward the segment’s growth.

• For instance, in September 2025, SCIEX launched Native fluorescence detection on BioPhase 8800 to enhance protein analysis. These products are aimed at monitoring critical quality attributes such as purity, fragmentation, aggregation, and post-translational modifications in protein therapeutics.

By Application

Increasing Focus on Protein Therapeutics to Boost Drug Discovery & Development Segments' Growth

Based on application, the market is segmented into drug discovery & development, proteomics & molecular biology, clinical diagnostics & disease research, and others.

The drug discovery & development segment held the dominating position in 2025. By application, the drug discovery & development segment held the share of 33.5% in 2025. The rising prevalence of chronic diseases and the focus of pharmaceutical and biotechnology industries to develop protein therapeutics for various diseases, such as oncology, autoimmune disorders, genetic diseases, and metabolic disorders.

• For instance, in January 2022, Amgen collaborated with Generate Biomedicines to generate USD 1.9 billion to discover and create protein therapeutics for five targets across several therapeutic areas.

The proteomics & molecular biology segment is set to flourish with a growth rate of 9.91% across the global protein assays market forecast period.

By End User

Patient Preference and Ease of Availability to Propel Drug Store and Retail Pharmacies Segments Growth

Based on end user, the market is segmented into pharmaceutical & biotechnology companies,

academic & research institutes, clinical & diagnostic laboratories, and others.

In 2025, the pharmaceutical & biotechnology companies segment is expected to witness a leading growth trajectory. The segment is set to hold 39.3% share in 2025. The rising drug discovery and development, and adoption of protein assays for detection, are expected to boost the adoption of these products in these settings.

In addition, academic & research institutes as end users are projected to grow at a CAGR of 5.99% during the study period. The increasing focus on protein studies to understand population proteomics is expected to boost the growth of the segment in the market.

• In January 2025, the U.K. Biobank announced the launch of a comprehensive study of the proteins circulating in our bodies, to transform the study of diseases and their treatments with the help of 5,400 proteins in each of 600,000 samples.

Protein Assays Market Regional Outlook

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

To get more information on the regional analysis of this market, Download Free sample

North America

North America held the dominant share in 2025, valued at USD 1.42 billion, and also took the leading share in 2026 with USD 1.63 billion. North America’s dominance in the market is driven by factors such as the presence of highly advanced infrastructure for research and development, with major players in the region. In 2025, the U.S. market is estimated to reach USD 1.35 billion.

The U.S. is expected to dominate the North America region's market. The rising proteomic research and presence of adequate funding and research environment boost the country’s growth in the market.

• For instance, in August 2025, VantAI, a company focused on programmable protein interactions, collaborated with Halda Therapeutics to accelerate the discovery and development of selective proximity-based therapies across cancer and immunology

Europe and Asia Pacific

Europe and Asia Pacific are anticipated to record a notable growth in the forthcoming years. During the forecast period, Europe is projected to record a growth rate of 7.08%, which is the second highest amongst all the regions, and touch the valuation of USD 0.71 billion in 2025. The primary factors driving the growth are the increasing research activities for proteomics and presence of active government support for research and development. Based on these factors, countries including the U.K. is expected to record a valuation of USD 0.16 billion, Germany is anticipated to record USD 0.14 billion, and France to record a valuation of USD 0.11 billion in 2025.

However, in 2025, Asia Pacific is estimated to reach USD 0.44 billion and secure the position of the third-largest region in the market. In the region, countries such as India and China are both estimated to reach USD 0.08 and USD 0.08 billion respectively in 2025.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa regions, on the other hand, would witness a moderate growth in this market over the forecast period. In 2025, the Latin America market is anticipated to record a valuation of USD 0.11 billion. Increasing focus of key players to shift their presence in the region to boost the market growth, but at a slower rate. In the Middle East & Africa, GCC is set to attain the value of USD 0.03 billion in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players:

Expansion of Product Offering and Strong Research and Development Activities to Maintain Their Position

The global market shows a fragmented structure with a large number of companies actively operating across the globe. These players have a robust product portfolio with strong research and development abilities.

Thermo Fisher Scientific Inc., Abcam Limited, and Agilent are among some of the dominating players in the market. The strong range of products and new product launches are expected to boost their position in the market.

Apart from this, other prominent players in the market include Bio-Rad Laboratories and Takara Bio, among other major key players in the market. These key players are focusing on offering various products for assays with kits and reagents to enhance their market presence.

LIST OF KEY PROTEIN ASSAYS COMPANIES PROFILED:

• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories (U.S.)
• Abcam Limited (U.K.)
• Agilent (U.S.)
• Merck KGaA (Germany)
• PerkinElmer (U.S.)
• Promega Corporation (U.S.)
• Takara Bio (Japan)

KEY INDUSTRY DEVELOPMENTS:

• September 2025: Quantum-Si Incorporated launched the V4 Sequencing Kit. The new kit is compatible with both the Platinum and Platinum Pro instruments used for protein sequencing and protein analysis.
• September 2025: Illumina Inc. unveiled Illumina Protein Prep, a new assay which offers enhanced performance for large-scale proteomics discovery using next-generation sequencing (NGS).
• February 2025: Alamar Biosciences launched NULISAqpcr Custom Assay Development Kit, to create highly sensitive and precise biomarker assays for research needs.
• December 2024: Syncell, raised USD 30 million to accelerate the commercialization of Microscoop platform. It is used for a high-precision, unbiased, spatial proteomic discovery in subcellular tissues or cells.
• January 2024: Agilent Technologies Inc. launched an automated parallel capillary electrophoresis system for protein analysis which improves the efficiency of analyzing complex protein mixtures.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation